Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma

Ren,Xiaojun; Su,Chunhong

doi:10.3892/mmr.2020.11295

Sphingosine kinase 1 contributes to doxorubicin resistance and glycolysis in osteosarcoma

Authors:
- Xiaojun Ren
- Chunhong Su
View Affiliations

Affiliations: Department of Pediatric Orthopedics, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China, Department of Pain, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China
Published online on: July 3, 2020 https://doi.org/10.3892/mmr.2020.11295
Pages: 2183-2190
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma (OS) is one of the most common and aggressive malignancies in children and adolescents worldwide. Sphingosine kinase 1 (SphK1) has recently been reported to serve a role in OS progression. The present study aimed to investigate the role of SphK1 in the development of chemoresistance and glycolysis in OS cell lines. SphK1 expression levels in OS cell lines (U2OS, MG63 and SaoS2) were analyzed using western blotting and reverse transcription‑quantitative PCR (RT‑qPCR). A cell survival assay was conducted to determine doxorubicin‑resistance in OS cells, and glycolysis was also evaluated. SphK1 expression was increased in the U2OS and SaoS2 cell lines, and both cell lines were more resistant to doxorubicin when compared with the MG63 cell line. SphK1 knockdown or overexpression altered doxorubicin resistance and the viability of OS cell lines. In addition, hypoxia inducible factor‑1α (HIF‑1α) expression was positively associated with SphK1 expression, and partly mediated SphK1‑induced effects on doxorubicin resistance and glycolysis. The present study suggested that SphK1 participated in the development of doxorubicin resistance and contributed to glycolysis in OS cells by regulating HIF‑1α expression. However, further studies investigating the application of SphK1 associated therapies for patients with OS are required.

View Figures

View References

1	He H, Ni J and Huang J: Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett. 7:1352–1362. 2014. View Article : Google Scholar : PubMed/NCBI
2	Ducreux M, Petersen LN, Ohler L, Bergamo F, Metges JP, de Groot JW, Wang JY, García Paredes B, Dochy E, Fiala-Buskies S, et al: Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. Eur J Cancer. 123:146–154. 2019. View Article : Google Scholar : PubMed/NCBI
3	Morrow JJ and Khanna C: Osteosarcoma genetics and epigenetics: Emerging biology and candidate therapies. Crit Rev Oncog. 20:173–197. 2015. View Article : Google Scholar : PubMed/NCBI
4	Sun K, Gong C, Peng H, Fang H, Zhou J, Li J, Chen S and Zheng H: High CCL5 expression is associated with osteosarcoma metastasis and poor prognosis of patients with osteosarcoma. Mol Med Rep. 16:6953–6957. 2017. View Article : Google Scholar : PubMed/NCBI
5	He F, Zhang W, Shen Y, Yu P, Bao Q, Wen J, Hu C and Qiu S: Effects of resection margins on local recurrence of osteosarcoma in extremity and pelvis: Systematic review and meta-analysis. Int J Surg. 36:283–292. 2016. View Article : Google Scholar : PubMed/NCBI
6	Buljan M, Blattmann P, Aebersold R and Boutros M: Systematic characterization of pan-cancer mutation clusters. Mol Syst Biol. 14:e79742018. View Article : Google Scholar : PubMed/NCBI
7	Heffernan-Stroud LA and Obeid LM: Sphingosine kinase 1 in cancer. Adv Cancer Res. 117:201–235. 2013. View Article : Google Scholar : PubMed/NCBI
8	Schiefler C, Piontek G, Doescher J, Schuettler D, Mißlbeck M, Rudelius M, Haug A, Reiter R, Brockhoff G and Pickhard A: Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR/SphK1 crosstalk. Oncotarget. 5:9877–9888. 2014. View Article : Google Scholar : PubMed/NCBI
9	Wang S, Liang Y, Chang W, Hu B and Zhang Y: Triple negative breast cancer depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-phosphate receptor 3 (S1PR3)/notch signaling for metastasis. Med Sci Monit. 24:1912–1923. 2018. View Article : Google Scholar : PubMed/NCBI
10	Hatoum D, Haddadi N, Lin Y, Nassif NT and McGowan EM: Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: Challenges for SphK as an oncotarget. Oncotarget. 8:36898–36929. 2017. View Article : Google Scholar : PubMed/NCBI
11	Chen J, Qi Y, Zhao Y, Kaczorowski D, Couttas TA, Coleman PR, Don AS, Bertolino P, Gamble JR, Vadas MA, et al: Deletion of sphingosine kinase 1 inhibits liver tumorigenesis in diethylnitrosamine-treated mice. Oncotarget. 9:15635–15649. 2018. View Article : Google Scholar : PubMed/NCBI
12	Wang F and Wu Z: Sphingosine kinase 1 overexpression is associated with poor prognosis and oxaliplatin resistance in hepatocellular carcinoma. Exp Ther Med. 15:5371–5376. 2018.PubMed/NCBI
13	Zhao Z, Ma J, Hu B, Zhang Y and Wang S: SPHK1 promotes metastasis of thyroid carcinoma through activation of the S1P/S1PR3/Notch signaling pathway. Exp Ther Med. 15:5007–5016. 2018.PubMed/NCBI
14	Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK and Robertson GP: Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 25:259–274. 2012. View Article : Google Scholar : PubMed/NCBI
15	Gault CR and Obeid LM: Still benched on its way to the bedside: Sphingosine kinase 1 as an emerging target in cancer chemotherapy. Crit Rev Biochem Mol Biol. 46:342–351. 2011. View Article : Google Scholar : PubMed/NCBI
16	Sun K, Zhang Y, D'Alessandro A, Nemkov T, Song A, Wu H, Liu H, Adebiyi M, Huang A, Wen YE, et al: Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia. Nat Commun. 7:120862016. View Article : Google Scholar : PubMed/NCBI
17	Cuvillier O, Ader I, Bouquerel P, Brizuela L, Gstalder C and Malavaud B: Hypoxia, therapeutic resistance, and sphingosine 1-phosphate. Adv Cancer Res. 117:117–141. 2013. View Article : Google Scholar : PubMed/NCBI
18	Xiong H, Wang J, Guan H, Wu J, Xu R, Wang M, Rong X, Huang K, Huang J, Liao Q, et al: SphK1 confers resistance to apoptosis in gastric cancer cells by downregulating Bim via stimulating Akt/FoxO3a signaling. Oncol Rep. 32:1369–1373. 2014. View Article : Google Scholar : PubMed/NCBI
19	Bao Y, Guo Y, Zhang C, Fan F and Yang W: Sphingosine Kinase 1 and Sphingosine-1-phosphate signaling in colorectal cancer. Int J Mol Sci. 18:21092017. View Article : Google Scholar
20	Li W, Li J, Wang Y, Zhang K, Li N, Tian Z, Ni B, Wang H and Ruan Z: Sphingosine kinase 1 is a potential therapeutic target for nasopharyngeal carcinoma. Oncotarget. 7:80586–80598. 2016. View Article : Google Scholar : PubMed/NCBI
21	Lu PH, Chen MB, Liu YY, Wu MH, Li WT, Wei MX, Liu CY and Qin SK: Identification of sphingosine kinase 1 (SphK1) as a primary target of icaritin in hepatocellular carcinoma cells. Oncotarget. 8:22800–22810. 2017. View Article : Google Scholar : PubMed/NCBI
22	Yao C, Wu S, Li D, Ding H, Wang Z, Yang Y, Yan S and Gu Z: Co-administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase-1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro. Mol Oncol. 6:392–404. 2012. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Nazouri AS, Asadpour O, Dabiri S, Pourseyedi B, Lashkarizadeh MR and Zianalinejad H: High expression of sphingosine kinase 1 in estrogen and progesterone receptors-negative breast cancer. Iran J Pathol. 12:218–224. 2017. View Article : Google Scholar : PubMed/NCBI
25	Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T and Cuvillier O: Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia. 20:95–102. 2006. View Article : Google Scholar : PubMed/NCBI
26	Katsuta E, Yan L, Nagahashi M, Raza A, Sturgill JL, Lyon DE, Rashid OM, Hait NC and Takabe K: Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. J Surg Res. 219:202–213. 2017. View Article : Google Scholar : PubMed/NCBI
27	Xu C, Zhang W, Liu S, Wu W, Qin M and Huang J: Activation of the SphK1/ERK/p-ERK pathway promotes autophagy in colon cancer cells. Oncol Lett. 15:9719–9724. 2018.PubMed/NCBI
28	Matula K, Collie-Duguid E, Murray G, Parikh K, Grabsch H, Tan P, Lalwani S, Garau R, Ong Y, Bain G, et al: Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer. 15:7622015. View Article : Google Scholar : PubMed/NCBI
29	Meng Y, Gao R, Ma J, Zhao J, Xu E, Wang C and Zhou X: MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy. Sci Rep. 7:4162017. View Article : Google Scholar : PubMed/NCBI
30	Kim M, Jung JY, Choi S, Lee H, Morales LD, Koh JT, Kim SH, Choi YD, Choi C, Slaga TJ, et al: GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy. Autophagy. 13:149–168. 2017. View Article : Google Scholar : PubMed/NCBI
31	Bernacchioni C, Ghini V, Cencetti F, Japtok L, Donati C, Bruni P and Turano P: NMR metabolomics highlights sphingosine kinase-1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells. Mol Oncol. 11:517–533. 2017. View Article : Google Scholar : PubMed/NCBI
32	Watson DG, Tonelli F, Alossaimi M, Williamson L, Chan E, Gorshkova I, Berdyshev E, Bittman R, Pyne NJ and Pyne S: The roles of sphingosine kinases 1 and 2 in regulating the Warburg effect in prostate cancer cells. Cell Signal. 25:1011–1017. 2013. View Article : Google Scholar : PubMed/NCBI
33	Ma Q, Zhang Y, Liu T, Jiang K, Wen Y, Fan Q and Qiu X: Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma. Cancer Biol Ther. 18:177–185. 2017. View Article : Google Scholar : PubMed/NCBI
34	Sowa T, Menju T, Chen-Yoshikawa TF, Takahashi K, Nishikawa S, Nakanishi T, Shikuma K, Motoyama H, Hijiya K, Aoyama A, et al: Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Cancer Med. 6:288–297. 2017. View Article : Google Scholar : PubMed/NCBI
35	Badowska-Kozakiewicz AM, Sobol M and Patera J: Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes. Arch Med Sci. 13:1303–1314. 2017. View Article : Google Scholar : PubMed/NCBI
36	Xie Y and Zhong DW: AEG-1 is associated with hypoxia-induced hepatocellular carcinoma chemoresistance via regulating PI3K/AKT/HIF-1alpha/MDR-1 pathway. Excli J. 15:745–757. 2016.PubMed/NCBI
37	Doublier S, Belisario DC, Polimeni M, Annaratone L, Riganti C, Allia E, Ghigo D, Bosia A and Sapino A: HIF-1 activation induces doxorubicin resistance in MCF7 3-D spheroids via P-glycoprotein expression: A potential model of the chemo-resistance of invasive micropapillary carcinom of the breast. BMC Cance. 12:42012. View Article : Google Scholar
38	Cao Y, Eble JM, Moon E, Yuan H, Weitzel DH, Landon CD, Nien CY, Hanna G, Rich JN, Provenzale JM and Dewhirst MW: Tumor cells upregulate normoxic HIF-1α in response to doxorubicin. Cancer Res. 73:6230–6242. 2013. View Article : Google Scholar : PubMed/NCBI
39	Ader I, Brizuela L, Bouquerel P, Malavaud B and Cuvillier O: Sphingosine kinase 1: A new modulator of hypoxia inducible factor 1alpha during hypoxia in human cancer cells. Cancer Res. 68:8635–8642. 2008. View Article : Google Scholar : PubMed/NCBI
40	Sevelda F, Mayr L, Kubista B, Lötsch D, van Schoonhoven S, Windhager R, Pirker C, Micksche M and Berger W: EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance. J Exp Clin Cancer Res. 34:1342015. View Article : Google Scholar : PubMed/NCBI